Targeting BC cells with the m6A inhibitor STM2457 combined with shRNA against PCAT6 or hnRNPA2B1 effectively inhibited the nuclear export of m6A‐tagged mRNA and ameliorated the malignant phenotypes of BCSCs. Here, HNRNPA2B1 is linked to breast cancer.